51 hasil untuk "Sweis, Randy F"
Menampilkan 1–20 · 0,23 detik · RSS
-
Artikel Jurnal Teks lengkap
Methods to assess anticancer immune responses in orthotopic bladder carcinomas
Urothelial bladder cancer is the most common malignancy of the urinary tract resulting in over 165,000 deaths worldwide. Immunotherapies targeting the programmed cell death protein-1 (PD-1) checkpoint pathway were recently approved for the treatment of bladder cancer, but favorable responses to…
-
Artikel Jurnal Teks lengkap
The Tumor Microenvironment of Bladder Cancer
Bladder cancer has been well known as immunotherapy-responsive disease as intravesical therapy with BCG has been the standard of care for non-muscle invasive disease for several decades. In addition, immune checkpoint inhibitors have dramatically changed the treatment of metastatic bladder cancer…
-
Artikel Jurnal Teks lengkap
FGFR3 Alterations in the Era of Immunotherapy for Urothelial Bladder Cancer
FGFR3 is a prognostic and predictive marker and is a validated therapeutic target in urothelial bladder cancer. Its utility as a marker and target in the context of immunotherapy is incompletely understood. We review the role of FGFR3 in bladder cancer and discuss preclinical and clinical clues of…
-
Artikel Jurnal Teks lengkap
The current and future role of systemic therapy in non–muscle‐invasive bladder cancer
Non–muscle‐invasive bladder cancer (NMIBC) categorizes early‐stage urothelial carcinoma that has not invaded the bladder's muscle layer. Although it is initially treatable with transurethral resection, NMIBC has a high risk of recurrence and progression, which necessitates prolonged surveillance…
-
Artikel Jurnal Teks lengkap
Low clinical adoption of tumor genomic profiling: cause for concern?
-
Artikel Jurnal Teks lengkap
Mechanistic and pharmacologic insights on immune checkpoint inhibitors
The concept of augmenting the immune system to eradicate cancer dates back at least a century. A major resurgence in cancer immunotherapy has occurred over the past decade since the identification and targeting of negative regulators with antibody therapies to augment the anti-tumor immune…
-
Artikel Jurnal Teks lengkap
Emerging role of immunotherapy in urothelial carcinoma - immunobiology/biomarkers
Urothelial bladder cancer is one of the first cancers recognized to be immunogenic since 40 years ago when the use of bacillus Calmette–Guerin (BCG) was shown to prevent recurrence. Since that time, our knowledge of immune biology of cancer has expanded tremendously, and bladder cancer patients…
-
Artikel Jurnal Teks lengkap
Analysis of Impact of Post-Treatment Biopsies in Phase I Clinical Trials
PURPOSE: The use of biopsy-derived pharmacodynamic biomarkers is increasing in early-phase clinical trials. It remains unknown whether drug development is accelerated or enhanced by their use. We examined the impact of biopsy-derived pharmacodynamic biomarkers on subsequent drug development through…
-
Artikel Jurnal Teks lengkap
The Development of STING Agonists and Emerging Results as a Cancer Immunotherapy
PURPOSE OF REVIEW: New therapies are needed to potentiate the effects of current immunotherapies and overcome resistance. The stimulator of interferon genes (STING)-pathway is an innate immune activating cascade that may enhance current cancer immunotherapies. RECENT FINDINGS: Pre-clinical data has…
-
Artikel Jurnal Teks lengkap
The Urinary Microbiome and Bladder Cancer: Susceptibility and Immune Responsiveness
Bladder cancer is a highly prevalent disease worldwide and is associated with a high mortality rate. Across all stages of bladder cancer, immunotherapy has now become the cornerstone of treatment. The commensal microbiome has become a major focus of research given its impact on numerous states of…
-
Artikel Jurnal Teks lengkap
T cell–inflamed versus non-T cell–inflamed tumors: a conceptual framework for cancer immunotherapy drug development and combination therapy selection
Immunotherapies such as checkpoint blocking antibodies and adoptive cell transfer are emerging as treatments for a growing number of cancers. Despite clinical activity of immunotherapies across a range of cancer types, the majority of patients fail to respond to these treatments and resistance…
-
Artikel Jurnal Teks lengkap
Characterization of oncogenic pathways linked with T cell exclusion in urothelial bladder cancer
-
Artikel Jurnal Teks lengkap
Concurrent EGFR Mutation and ALK Translocation in Non-Small Cell Lung Cancer
Epidermal growth factor receptor (EGFR) mutations and anaplastic large-cell lymphoma kinase (ALK) rearrangements are now routine biomarkers that have been incorporated into the practice of managing non-small cell lung cancer (NSCLC). Historically, the two molecular alterations have been viewed as…
-
Artikel Jurnal Teks lengkap
A global method for fast simulations of molecular dynamics in multiscale agent-based models of biological tissues
Agent-based models (ABMs) are a natural platform for capturing the multiple time and spatial scales in biological processes. However, these models are computationally expensive, especially when including molecular-level effects. The traditional approach to simulating this type of multiscale ABM is…
-
Artikel Jurnal Teks lengkap
Morphological Correlation of Urinary Bladder Cancer Molecular Subtypes in Radical Cystectomies
Several molecular subtypes of bladder cancer were identified with differing clinical behavior and responses to platinum-based chemotherapy. But so far, their urothelial histomorphologic features, besides association to some variant histologies, remained fully undefined. We sought to characterize…
-
Artikel Jurnal Teks lengkap
Cost-Effectiveness of Immune Checkpoint Inhibitors in Urothelial Carcinoma—A Review
SIMPLE SUMMARY: Urothelial carcinoma is a malignancy that originates in the genitourinary tract. It is a heterogeneous disease that can present at different stages, and the treatment options vary in efficacy. Advances in immunotherapy stimulated adoption in urothelial carcinoma, and published…
-
Artikel Jurnal Teks lengkap
A validated mathematical model of FGFR3-mediated tumor growth reveals pathways to harness the benefits of combination targeted therapy and immunotherapy in bladder cancer
Bladder cancer is a common malignancy with over 80,000 estimated new cases and nearly 18,000 deaths per year in the United States alone. Therapeutic options for metastatic bladder cancer had not evolved much for nearly four decades, until recently, when five immune checkpoint inhibitors were…
-
Artikel Jurnal Teks lengkap
Mathematical model predicts tumor control patterns induced by fast and slow cytotoxic T lymphocyte killing mechanisms
Immunotherapy has dramatically transformed the cancer treatment landscape largely due to the efficacy of immune checkpoint inhibitors (ICIs). Although ICIs have shown promising results for many patients, the low response rates in many cancers highlight the ongoing challenges in cancer treatment…
-
Artikel Jurnal Teks lengkap
Complete response of renal cell carcinoma vena cava tumor thrombus to neoadjuvant immunotherapy
BACKGROUND: Clinically localized renal cell carcinoma is treated primarily with surgery followed by observation or adjuvant sunitinib in selected high-risk patients. The checkpoint inhibitor immunotherapeutic agents nivolumab and ipilimumab have recently shown a survival benefit in the first-line…
-
Artikel Jurnal Teks lengkap
Molecular Drivers of the Non-T Cell-Inflamed Tumor Microenvironment in Urothelial Bladder Cancer
Muscle-invasive urothelial bladder cancer is a common malignancy with poor outcomes for which immune checkpoint blockade is now showing promise. Despite clinical activity of PD-1/PD-L1-targeted therapy in this disease, most patients do not benefit and resistance mechanisms remain unknown. The non-T…